Special brain scans using hyperpolarized pyruvate in people with meningioma
Tests whether special MRI scans can show tumor metabolism in adults with meningioma.
Key facts
- Who runs it
- Charlie Wang, MD, PhD
- Where
- San Francisco, United StatesSee the site
- Trial code
- Registry title
- Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 50 people, planned
- Started
- 1 Sept 2023
- Expected to end
- 30 Sept 2027
- Type of study
- Interventional
- Treatments tested
- Hyperpolarized carbon C 13 pyruvate
- Magnetic Resonance Image (MRI)
- Saline
- Record updated
- 14 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with meningioma, a tumour of the brain's lining. They will have one research MRI scan with an injected tracer called HP 13C pyruvate.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Meningioma confirmed by tissue test or likely from imaging. The tumour must show on MRI with contrast, at least one cm across, inside the skull and not only at the skull base. Thirty participants plan to have surgery to remove the tumour within 4 weeks.
- Biomarker or test result
- Creatinine (a kidney blood test) must be below 1.5 mg/dL (133 µmol/L), tested within 60 days before the scan.
Main reasons for not taking part
- Cannot have an MRI scan
- Expected to live 12 weeks or less, or Karnofsky Performance Status (a score of daily activity) of 60% or lower
- Blood pressure at or above 140 mmHg systolic or 90 mmHg diastolic despite medicines
- Another cancer in the past, unless in complete remission and off treatment for at least 3 years (non-melanoma skin cancer and carcinoma in-situ of the cervix are allowed)
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Known (histopathologically confirmed) or presumed meningioma based on imaging with measurable disease on MRI that shows gadolinium enhancement (at least one cm diameter) intracranially (e.g., not confined to skull base alone); Thirty of the participants plan to have surgical resection within 4 weeks
- Participants cannot have contraindication to MRI examinations
- Age >=18 years
- Have a life expectancy of >12 weeks
- Karnofsky Performance Status > 60%
- Participants must have adequate renal function (creatinine < 1.5 mg/dL) before imaging. This test must be performed within 60 days prior to hyperpolarized imaging scan
- Participants must sign an informed consent indicating that they are aware of the investigational nature of this study
- Participants must sign an authorization for the release of their protected health information
Who cannot take part
- Uncontrolled blood pressure (Systolic BP≥140 mmHg or diastolic BP ≥>=90 mmHg) despite an optimized regimen of antihypertensive medication
- Has any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy, would compromise the patient's ability to participate in this study or any disease that will obscure toxicity or dangerously impact response to the imaging agent
- Has a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off of all therapy for that disease for a minimum of 3 years
- Participants must not be pregnant or breast feeding. Women of childbearing potential are required to obtain a negative pregnancy test within 14 days of Hyperpolarized Imaging scan. Effective contraception (men and women) must be used in participants of child-bearing potential
- Participants must be excluded from participating in the study if they are not able to comply with the study and/or follow-up procedures
Where in United States
- University of California San FranciscoSan Francisco, United StatesContact: Wendy MaTaking people
About the trial
What the trial wants to find out
This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that includes the acquisition of magnetic resonance (MR) data performed on participants with meningioma to evaluate metabolism and aid in the non-invasive characterization of aggressive tumor behavior
The group in the trial
- Hyperpolarized 13C pyruvate, Magnetic Resonance ImagingTreatment being tested
Participants will receive a single research MR imaging using HP 13C pyruvate, intravenously injected at a rate of 5 ml/second followed by a 20-ml saline flush at 5 ml/second. Safety monitoring, including vital signs and symptom monitoring will be performed for 30 minutes after dosing is completed, 1 to 3 days after dosing, and up to 30 days post scanning procedure. During the follow-up period, study personnel will obtain clinical data from the participants' medical records.
Treatment: Hyperpolarized carbon C 13 pyruvate, Magnetic Resonance Image (MRI), and Saline
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Pilot/Phase I Study of Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
- Plain-language title
- Special brain scans using hyperpolarized pyruvate in people with meningiomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 14 August 2026